Fresh enthusiasm for Cerecor sours as lead drug flops in PhII depression study, shares crater
A few weeks ago, investors embraced shares of Cerecor in the big surge that swept up Alkermes’ stock following its clinical success for an anti-depression drug that bore some striking resemblances to one of the microcap’s experimental depression treatments, CERC-501, in-licensed for a small upfront from Eli Lilly.
But that comforting comparison gave way to a disappointing reality Tuesday evening as Cerecor reported that its lead depression drug in the pipeline — CERC-301 — flopped in a mid-stage study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.